SCHEMBL6784709

SCHEMBL6784709

C/C(=C/C(=O)Nc1ccc(F)cc1C(=O)O)c1ccc(C)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.46
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
DHODH Q02127 6/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GFER P55789 1/20 0.42
KCNK2 O95069 1/20 0.42
AVPR2 P30518 1/20 0.42
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
CLCN2 P51788 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPM2 O94759 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6788013 0.85 TERT (0.62) TERTDHODHMEN1KMT2AALDH1A1
SCHEMBL6785899 0.83 TERT (0.54) TERTDHODHMEN1KMT2AALDH1A1
SCHEMBL6792275 0.81 PPARG (0.53) TERTPPARGPPARADHODHAVPR2
SCHEMBL6785956 0.80 TERT (0.53) TERTDHODHKCNK2CLCN2KDM4E
SCHEMBL6790635 0.80 TERT (0.52) TERTDHODHKCNK2TRPM2
SCHEMBL6790504 0.78 TERT (0.62) TERTDHODHCLCN2
SCHEMBL4020296 0.77 TERT (0.77) TERTDHODHKCNK2KDM4E
SCHEMBL6782589 0.77 DHODH (0.58) TERTDHODHMEN1KMT2AALDH1A1
SCHEMBL6783775 0.76 TERT (0.54) TERTPPARGPPARAMEN1KMT2A
SCHEMBL6781608 0.76 CYP3A4 (0.53) TERTMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885PPARG 151/4885PPARA 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.